To decrease this risk, TALEN gene-editing technology was used to produce a TCRαβ-negative allogeneic CD123 CAR (UCART 123); these CAR-T cells preferentially eliminate AML over normal cells with minimal toxicity to normal hematopoietic stem/progenitor cells [116]. This evidence concerns the gene IL3RA and acute myeloid leukemia.